Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has announced a significant milestone in its ACCENT trial, which is evaluating the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has recorded a second complete response, a rare outcome in this disease, highlighting the potential of narmafotinib to enhance treatment efficacy and improve patient outcomes. This development underscores Amplia’s progress in targeting fibrotic cancers and solidifies its position in the oncology sector.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 2,267,737
Technical Sentiment Signal: Sell
Current Market Cap: A$25.6M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue